Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Thomas, Douglas D.

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


IMPACT FACTOR 2016: 3.273

CiteScore 2016: 3.01

SCImago Journal Rank (SJR) 2015: 1.607
Source Normalized Impact per Paper (SNIP) 2015: 0.751

Online
ISSN
1437-4315
See all formats and pricing
In This Section
Volume 387, Issue 2 (Feb 2006)

Issues

Genetically altered animal models in the kallikrein-kinin system

João B. Pesquero
  • Department of Biophysics, Universidade Federal de São Paulo, São Paulo, CEP 04023-062, Brazil
/ Michael Bader
  • Max-Delbrück Center for Molecular Medicine, D-13125 Berlin, Germany
Published Online: 2006-02-09 | DOI: https://doi.org/10.1515/BC.2006.017

Abstract

Transgenic and gene-targeting technologies allowing the generation of genetically altered animal models have greatly advanced our understanding of the function of specific genes. This is also true for the kallikrein-kinin system (KKS), in which some, but not yet all, components have been functionally characterized using such techniques. The first genetically altered animal model for a KKS component was supplied by nature, the brown Norway rat carrying an inactivating mutation in the kininogen gene. Mice deficient in tissue kallikrein, B1 and B2 receptors, some kinin-degrading enzymes, and factor XII followed, together with transgenic rat and mouse strains overexpressing tissue kallikrein, B1 and B2 receptors, and degrading enzymes. There are still no animal models with genetic alterations in plasma kallikrein, kininases I and some other degrading enzymes. The models have confirmed an important role of the KKS in cardiovascular pathology, inflammation, and pain, and have partially elucidated the distinct function of the two receptors. This created the basis for rational decisions concerning the putative use of kinin receptor agonists and antagonists in therapeutic applications. However, a more thorough analysis of the existing models and the generation of new, more sophisticated transgenic models will be necessary to clarify the still elusive issue as to where and by which mechanisms the kinins exert their actions.

Keywords: bradykinin; kininase; kininogen; kinin receptor; knockout animals; transgenic animals

References

About the article

Corresponding author


Published Online: 2006-02-09

Published in Print: 2006-02-01



Citation Information: Biological Chemistry, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2006.017. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
P. Hillmeister and P. B. Persson
Acta Physiologica, 2012, Volume 206, Number 4, Page 215
[2]
Domenico Regoli, Gerard E. Plante, and Fernand Gobeil
Pharmacology & Therapeutics, 2012, Volume 135, Number 1, Page 94
[3]
Benoit Bourdet, Christiane Pécher, Vincent Minville, Acil Jaafar, Julien Allard, Nelly Blaes, Jean-Pierre Girolami, and Ivan Tack
Neuropeptides, 2010, Volume 44, Number 2, Page 155
[4]
Francisco L. Pontes, Reury F.P. Bacurau, Milton R. Moraes, Francisco Navarro, Dulce E. Casarini, Jorge L. Pesquero, João B. Pesquero, Ronaldo C. Araújo, and Ivan C. Piçarro
International Immunopharmacology, 2008, Volume 8, Number 2, Page 261
[6]
Rodrigo A. Loiola, Felipe C.G. Reis, Elisa M. Kawamoto, Cristoforo Scavone, Dulcinéia S. Abdalla, Liliam Fernandes, and João Bosco Pesquero
Peptides, 2011, Volume 32, Number 8, Page 1700
[7]
Sandra Lauton-Santos, Silvia Guatimosim, Carlos H. Castro, Fernando A. Oliveira, Alvair P. Almeida, Marco Fabrício Dias-Peixoto, Maria Aparecida Gomes, Phillipe Pessoa, Jorge L. Pesquero, João B. Pesquero, Michael Bader, and Jader S. Cruz
Life Sciences, 2007, Volume 81, Number 10, Page 814
[8]
Maria M. Campos, Paulo C. Leal, Rosendo A. Yunes, and João B. Calixto
Trends in Pharmacological Sciences, 2006, Volume 27, Number 12, Page 646
[9]
Michael Bader
Annual Review of Pharmacology and Toxicology, 2010, Volume 50, Number 1, Page 439
[10]
Viktor Brovkovych, Yongkang Zhang, Svitlana Brovkovych, Richard D. Minshall, and Randal A. Skidgel
Journal of Cellular and Molecular Medicine, 2011, Volume 15, Number 2, Page 258
[11]
Milton R. Moraes, Reury F.P. Bacurau, João D.S. Ramalho, Felipe C.G. Reis, Dulce E. Casarini, Jair R. Chagas, Vitor Oliveira, Elisa Mieko S. Higa, Dulcinéia S.P. Abdalla, Jorge L. Pesquero, João B. Pesquero, and Ronaldo C. Araujo
Biological Chemistry, 2007, Volume 388, Number 5
[12]
Marcelo Alves-da-Silva Mori, Michael Bader, and João Bosco Pesquero
Current Opinion in Nephrology and Hypertension, 2008, Volume 17, Number 1, Page 11
[13]
Cleber A. Trujillo, Telma T. Schwindt, Antonio H. Martins, Janaína M. Alves, Luiz Eugênio Mello, and Henning Ulrich
Cytometry Part A, 2009, Volume 75A, Number 1, Page 38
[14]
Philipp Hillmeister, Kerstin E Lehmann, Anja Bondke, Henning Witt, André Duelsner, Clemens Gruber, Hans-Jörg Busch, Joachim Jankowski, Patricia Ruiz-Noppinger, Konstantin-Alexander Hossmann, and Ivo R Buschmann
Journal of Cerebral Blood Flow & Metabolism, 2008, Volume 28, Number 11, Page 1811
[15]
Paolo Madeddu, Costanza Emanueli, and Samir El-Dahr
Nature Clinical Practice Nephrology, 2007, Volume 3, Number 4, Page 208

Comments (0)

Please log in or register to comment.
Log in